In Cluj (Romania), we recruited a cohort of 250 patients with established symptomatic stable coronary artery disease.

In Cluj (UMF, Romania), we recruited a cohort of 250 patients with established symptomatic stable coronary artery disease, angiographically documented coronary atherosclerosis, and no past history of acute thrombotic events (acute myocardial infarction, stroke, acute limb ischemia). We performed clinical follow up for 2 years. In addition to the baseline clinical characteristics, we have isolated monocytes from all subjects to perform ex vivo stimulation to measure cytokine production capacity, and we have performed flow cytometry to look at the distribution of the monocyte subsets. In addition, we are currently analysing metabolome, and whole genome from all individuals.

Complete data, including the 2 years clinical follow-up, is currently available for the first 113 patients. Preliminary results show already a significant association between the subpopulation of classical CD14+/CD16- monocytes and the rate of MACE (acute myocardial infarction, unstable angina, stroke, transient ischemic attack, acute limb ischemia, myocardial revascularization, and cardiovascular death) (P=0.03). Elevated classical CD14+/CD16- monocytes were previously associated with cardiovascular events independently of age, waist, BMI, diabetes, glycemic and creatinine values. Collection and analysis of the complete data set is still ongoing and expected to be published in the Winter of 2019-2020.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.